HC Wainwright Has Pessimistic Outlook of NTLA Q1 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Investment analysts at HC Wainwright reduced their Q1 2026 earnings per share estimates for shares of Intellia Therapeutics in a report released on Monday, March 2nd. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.97) for the quarter, down from their prior estimate of ($0.93). HC Wainwright currently has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ Q2 2026 earnings at ($0.88) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.91) EPS and FY2026 earnings at ($3.71) EPS.

Several other research firms have also recently weighed in on NTLA. Leerink Partners boosted their price objective on shares of Intellia Therapeutics from $27.00 to $29.00 and gave the company an “outperform” rating in a report on Tuesday. Wedbush decreased their target price on shares of Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. William Blair upgraded Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday. Wolfe Research reiterated a “peer perform” rating on shares of Intellia Therapeutics in a research report on Wednesday, November 12th. Finally, JonesTrading raised Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $29.00 target price on the stock in a report on Wednesday. Eleven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $19.59.

Intellia Therapeutics Stock Performance

NTLA opened at $13.82 on Wednesday. The company’s 50-day simple moving average is $12.17 and its two-hundred day simple moving average is $13.10. The stock has a market capitalization of $1.63 billion, a P/E ratio of -3.61 and a beta of 2.10. Intellia Therapeutics has a 52-week low of $5.90 and a 52-week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The company had revenue of $23.02 million for the quarter, compared to analysts’ expectations of $12.17 million. During the same period last year, the firm posted ($1.27) earnings per share. Intellia Therapeutics’s revenue was up 78.4% compared to the same quarter last year.

Hedge Funds Weigh In On Intellia Therapeutics

Several large investors have recently made changes to their positions in the business. Comerica Bank grew its position in shares of Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after purchasing an additional 901 shares in the last quarter. Headlands Technologies LLC bought a new position in Intellia Therapeutics in the 2nd quarter worth approximately $26,000. Blue Bell Private Wealth Management LLC bought a new stake in shares of Intellia Therapeutics during the third quarter valued at approximately $30,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Intellia Therapeutics during the third quarter valued at approximately $30,000. Finally, Advisory Services Network LLC purchased a new position in shares of Intellia Therapeutics in the third quarter worth $33,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP James Basta sold 10,397 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $95,756.37. Following the sale, the executive vice president directly owned 101,528 shares in the company, valued at $935,072.88. This trade represents a 9.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John M. Leonard sold 34,146 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $314,484.66. Following the completion of the transaction, the chief executive officer directly owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. This represents a 3.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 53,051 shares of company stock valued at $488,600. 3.10% of the stock is owned by corporate insiders.

Intellia Therapeutics News Roundup

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds / allows second in‑human trial to resume, removing a major regulatory overhang and clearing Intellia to restart an important gene‑editing program. Read More. Read More.
• Positive Sentiment: Multiple analyst upgrades and target increases (JonesTrading to Buy, Leerink & HC Wainwright bumping targets, William Blair upgrade to Outperform) have supported sentiment and likely drove buying interest. JonesTrading set a $29 PT; HC Wainwright raised its PT to $30. Read More. Read More.
• Positive Sentiment: Intellia presented longer‑term clinical data for lonvoguran (lonvo‑z) at AAAAI showing multi‑year follow‑up after a one‑time dose — reinforces the durability narrative for a key therapeutic candidate. Read More.
• Positive Sentiment: High‑profile investor interest: Cathie Wood’s Ark (coverage piece) noted buying activity in beaten‑up growth names, including Intellia — a potential source of additional demand from momentum/growth investors. Read More.
• Neutral Sentiment: Other broker moves mixed: RBC, Wells Fargo and others nudged targets modestly higher (to ~$15), while Canaccord cut its target from $54 to $48 — consensus remains wide, reflecting varying views on timelines and commercialization risk. Read More.
• Negative Sentiment: HC Wainwright trimmed near‑term EPS estimates across several 2026 quarters and lowered full‑year forecasts slightly even while maintaining a Buy and a $30 PT — a reminder analysts expect continued cash burn and negative earnings into 2026. This raises execution risk and could limit multiple expansion. Read More.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.